-
1 Comment
From a valuation standpoint, the stock is 95.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.1.
Based on the above factors, Viridian Therapeutics, Inc gets an overall score of 1/5.
| ISIN | US92790C1045 |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Market Cap | 1B |
|---|---|
| Beta | 0.97 |
| Dividend Yield | 0.0% |
| Target Price | 46.85 |
| PE Ratio | None |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VRDN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
